Azenta’s Q2 results were met with a significant negative market reaction following a flat sales performance that missed Wall Street’s revenue expectations. Management attributed the lack of growth to persistent macroeconomic pressures and delayed customer purchasing decisions, particularly in its core product lines. CEO John Marotta described the environment as one of "funding constraints, supply chain complexities or market uncertainties," with growth primarily coming from next-generation sequencing and sample storage. Despite these headwinds, the company demonstrated operational improvements, reflected in higher adjusted EBITDA margins and reduced general and administrative costs.
Is now the time to buy AZTA? Find out in our full research report (it’s free).
Azenta (AZTA) Q2 CY2025 Highlights:
- Revenue: $143.9 million vs analyst estimates of $149.6 million (flat year on year, 3.8% miss)
- Adjusted EPS: $0.14 vs analyst estimates of $0.14 (in line)
- Adjusted EBITDA: $17.66 million vs analyst estimates of $17.29 million (12.3% margin, 2.2% beat)
- Operating Margin: -0.5%, up from -4.9% in the same quarter last year
- Market Capitalization: $1.34 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Azenta’s Q2 Earnings Call
- David Joshua Saxon (Needham): Asked about the confidence behind the implied revenue step-up next quarter and potential outlook for the following year. CFO Lawrence Lin explained visibility comes from a strong backlog and order timing, but stressed that execution will be key to achieving targets.
- Hannah Webb Hefley (Stephens Inc.): Inquired about the causes and resolution of softness in Gene Synthesis. CEO John Marotta clarified that delays are mostly timing related, with some improvement expected soon, and there are no significant order cancellations.
- Vijay Muniyappa Kumar (Evercore): Questioned the impact of new commercial leadership on order flow and sales execution. Marotta discussed recent sales leadership hires and the shift to a regional commercial model, citing early signs of improved customer engagement.
- Brendan Mychal Smith (TD Cowen): Probed for visibility on the sales funnel and areas of strength in end-market spending. Marotta emphasized that the funnel is robust, with no order cancellations and solid execution in capital equipment, but the timing of customer budgets remains unpredictable.
- Matthew Jay Stanton (Jefferies): Sought details on next-generation sequencing growth drivers and the durability of outsourcing trends. Marotta pointed to strong sales execution and growing demand for outsourcing from both academic and pharma customers, especially as clients seek operational efficiencies.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be watching (1) the pace of order conversion from backlog and the resolution of delayed customer purchases, (2) the impact of ongoing investments in R&D and commercial leadership on both revenue growth and margin performance, and (3) signs of stabilization or improvement in funding environments for life sciences customers. Progress on strategic M&A and continued cost discipline will also be key indicators of execution.
Azenta currently trades at $30.99, down from $32.41 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
